These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7751433)

  • 21. Sex and age differences in the pharmacokinetics of alosetron.
    Koch KM; Palmer JL; Noordin N; Tomlinson JJ; Baidoo C
    Br J Clin Pharmacol; 2002 Mar; 53(3):238-42. PubMed ID: 11874386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.
    Miura M; Lawson DC; Clary EM; Mangel AW; Pappas TN
    Dig Dis Sci; 1999 Jan; 44(1):20-4. PubMed ID: 9952218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
    Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
    Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
    Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
    Koch KM; Corrigan BW; Manzo J; James CD; Scott RJ; Stead AG; Kersey KE
    Aliment Pharmacol Ther; 2004 Jul; 20(2):223-30. PubMed ID: 15233703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: effects of the 5-HT3 receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle.
    Audolfsson G; Bayguinov O; Yamamoto T; Somogyi GT; Schraut WH; Sanders KM; Bauer AJ
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():39-47. PubMed ID: 10429739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat.
    Grundy D; McLean P; Stead R
    Neurogastroenterol Motil; 2007 Jul; 19(7):607-16. PubMed ID: 17593142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.
    Kozlowski CM; Green A; Grundy D; Boissonade FM; Bountra C
    Gut; 2000 Apr; 46(4):474-80. PubMed ID: 10716675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
    Bush TG; Spencer NJ; Watters N; Sanders KM; Smith TK
    Am J Physiol Gastrointest Liver Physiol; 2001 Oct; 281(4):G974-83. PubMed ID: 11557518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.
    Saslow SB; Scolapio JS; Camilleri M; Forstrom LA; Thomforde GM; Burton DD; Rubin J; Pitot HC; Zinsmeister AR
    Gut; 1998 May; 42(5):628-34. PubMed ID: 9659155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
    Nakai A; Diksic M; Kumakura Y; D'Souza D; Kersey K
    Neurogastroenterol Motil; 2005 Apr; 17(2):212-21. PubMed ID: 15787942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
    Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK
    Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inward currents in neurons from newborn guinea pig intestine: mediation by 5-hydroxytryptamine type 3 receptors.
    Zhai J; Gershon MD; Walsh JH; Wong HC; Kirchgessner AL
    J Pharmacol Exp Ther; 1999 Oct; 291(1):374-82. PubMed ID: 10490927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.